FEBS Open Bio (Jul 2022)

G‐CSF/GM‐CSF‐induced hematopoietic dysregulation in the progression of solid tumors

  • Kai He,
  • Xi Liu,
  • Robert D. Hoffman,
  • Rong‐Zhen Shi,
  • Gui‐Yuan Lv,
  • Jian‐Li Gao

DOI
https://doi.org/10.1002/2211-5463.13445
Journal volume & issue
Vol. 12, no. 7
pp. 1268 – 1285

Abstract

Read online

There are two types of abnormal hematopoiesis in solid tumor occurrence and treatment: pathological hematopoiesis, and myelosuppression induced by radiotherapy and chemotherapy. In this review we primarily focus on the abnormal pathological hematopoietic differentiation in cancer induced by tumor‐released granulocyte colony‐stimulating factor (G‐CSF) and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). As key factors in hematopoietic development, G‐CSF/GM‐CSF are well‐known facilitators of myelopoiesis and mobilization of hematopoietic stem cells (HSCs). In addition, these two cytokines can also promote or inhibit tumors, dependent on tumor type. In multiple cancer types, hematopoiesis is greatly enhanced and abnormal lineage differentiation is induced by these two cytokines. Here, dysregulated hematopoiesis induced by G‐CSF/GM‐CSF in solid tumors and its mechanism are summarized, and the prognostic value of G‐CSF/GM‐CSF‐associated dysregulated hematopoiesis for tumor metastasis is also briefly highlighted.

Keywords